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Natural killer (NK) cells play a critical role in innate anti-viral immunity,but little is known about the impact of anti-viral therapy
on the frequency of NK cell subsets. To this aim, we performed this longitudinal study to exam the dynamic changes of the
frequency of diﬀerent subsets of NK cells in CHB patients after initiation of tenofovir or adefovir therapy. We found that NK
cell numbers and subset distribution diﬀer between CHB patients and normal subjects, furthermore the association was found
between ALT level and CD158b+ NK cell in HBV patients. In tenofovir-group, the frequency of NK cells were increased during the
treatment accompanied downregulated expression of NKG2A and KIR2DL3. In adefovir-group, NK cell numbers did not diﬀer
during the treatment, but also accompanied downregulated expression of NKG2A and KIR2DL3.Our results demonstrate that
treatment with tenofovir leads to viral load reduction, and correlated with NK cell frequencies in peripheral blood of chronic
hepatitis B virus infection. In addition, treatments with both tenofovir and adefovir in chronic HBV infected patients induce a
decrease of the frequency of inhibitory receptor+ NK cells, which may account for the partial restoration of the function of NK
cells in peripheral blood following treatment.
1. Introduction
Chronic infection with hepatitis B virus (HBV) aﬀects more
than 350 million people worldwide and continues to be
an important cause of morbidity and mortality [1]. The
current therapy for chronic hepatitis B (CHB) is based
on the use of immunomodulators like pegylated interferon
or nucleos(t)ide analogues (NUCs) that inhibit both the
priming and the elongation steps of viral DNA replication
[2–10].
The high cost, side eﬀects, and the fact that potent antivi-
ral response can be only achieved in a minor population of
patients limit the clinical use of PEG-IFN. In addition, as
the oﬀ-treatment durability of response to NUCs is generally
low, it is required to maintain a long-term continuous
therapy when patients treated with NUCs. However, long-
term continuous therapy with NUCs carries significant risks
of occurrence of viral resistance, drug toxicity as well as
unsustainable cost for many of the most heavily aﬀected
countries. All of these guidelines support both NUCs and
PEG-IFN as first-line treatment options, but the optimal
choice for individual patients remains controversial.
The choice of therapy is determined by many factors
including the stage of the disease, serum alanine transami-
nase (ALT), HBV DNA levels, and eAg status of the patient.
Both Tenofovir (tenofovir disoproxil fumarate) and Adefovir
dipivoxil are very potent and eﬀective nucleotide analog
against HBV [9, 11, 12]. But in clinical studies, Tenofovir
displayed higher intrinsic potency than Adefovir dipivoxil
[12]. Immunologic mechanisms involved in the control of
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HBV replication in vivo are not yet completely under-
stood [13–17]. Understanding the mechanisms of therapy-
induced antiviral immune responses could further direct
novel therapeutic strategies [18]. Most studies examined the
functionality of HBV-specific CD4+ T cells and regulatory T
cells in blood of patients and found that their functionality is
improved in NUC-treated CHB patients [19–22]. However,
this eﬀect was only transient [23]. Besides, HBV-specific T
cells also natural killer (NK) are important eﬀector cells
during antiviral immune responses [24]. An early rise in
circulating NK cells has been documented in the incubation
phase of HBV infection, suggesting that they may contribute
to the initial viral containment in this setting [25]. NK
cells are innate immune cells and play important roles in
the defense against viral infections. They can kill virus-
infected cells directly as well as indirectly via antibody-
dependent, cell-mediated cytotoxicity. They do not need
prior sensitization and expansion for this killing. In humans,
NK cells are usually defined as CD3−CD56+ lymphocytes
and are comprised of about 5%–20% of peripheral blood
lymphocytes. However, the frequency of NK cells in intra-
hepatic lymphocytes can increase to about 30%–50% [26].
NK cells are a diverse population and NK cells do not
possess a single well-defined receptor to recognize antigens
on target cells like T cells. Instead, their function depends
on the expression of activating and inhibitory receptors
that recognize various classes of cell surface ligands [27].
These ligands include classical and nonclassical MHC class
I antigens, MHC-like proteins, and a variety of other
self- and virus-derived molecules. They may be expressed
constitutively and/or de novo on the surface of virus-infected
cells.
Only limited information has been published on the role
of NK cells in HBV infection. In acute HBV, an early rise
in circulating NK cells has been documented, suggesting
their contribution to the initial viral containment [25, 28,
29]. In the context of persistent HBV infection, NK cell
studies mainly focused on NK cell induced tissue injury
[30, 31]. However, very little is known about the quality
of the antiviral functions of NK cells during chronic HBV.
It has recently shown that inhibition of chronic hepatitis
B virus replication by antiviral therapeutic medicine such
as entecavir, lamivudine, and adefovir helps to partially
restore function of NK cells in peripheral blood [32, 33].
This restoration of NK cell activity was accompanied by an
enhanced frequency of IFN-γ-producing CD56+ NK cells in
blood as well as normalization of the expression of the acti-
vating receptor NKG2A on circulating NK cells. Controlling
of viral replication by antiviral treatment can partially correct
this defect but little is known about the impact of antiviral
therapy on the frequency of diﬀerent subsets of NK cells. To
this aim, we performed this longitudinal study to examine
the dynamic changes of the frequency of diﬀerent subsets
of NK cells in CHB patients after initiation of tenofovir
or adefovir therapy. We found that NK cell numbers and
subset distribution diﬀer between CHB patients and normal
subjects, furthermore the association was found between
ALT level and CD158b+ NK cell in HBV patients. In
CHB patients treatment with tenofovir, the frequency of
NK cells was increased during the treatment, accompanied
downregulated expression of NKG2A and KIR2DL3, which
correlated with serum HBV-DNA load. In CHB patients
treatment with adefovir, NK cell numbers did not diﬀer
during the treatment, but also accompanied downregulated
expression of NKG2A and KIR2DL3.
2. Patients andMethods
2.1. Patients and Healthy Subjects. A total of 24 CHB
patients and 12 gender- and age-matched healthy subjects
were recruited at the outpatient clinic of the Department
of Hepatology of the First Hospital of Jilin University,
China from May 2011 to October 2011. Individual patients
with CHB were diagnosed, according to the criteria of
detectable HBV virions and HBeAg positive or negative
(HBVDNA ≥ 105 copies/mL, an interval of 14 days or
more than twice elevated ALT of HBeAg-positive patients ≥
2ULN(upper limit of normal); HBeAg-negative patients >
1ULN and ≤ 10ULN). There are seven HBeAg-positive
patients in TDF-group and eight in ADV-group. All the
24 patients were previously untreated. Individuals with a
history of hepatitis C and hepatitis D, positive antibodies
against HCV and HDV, human Immunodeficiency virus
(HIV), or other inflammatory diseases, such as rheuma-
toid arthritis, diabetes, autoimmune hepatitis, hypertension,
kidney disease, or recent infectious diseases were excluded.
Written informed consent was obtained from all patients,
and the experimental protocol was approved by the Ethics
Committee of the First Hospital of Jilin University.
2.2. Treatment. Individual patients with CHB were ran-
domized and treated with tenofovir disoproxil fumarae
(GSK Pharma UK) 300mg once daily. Another group of
patients with CHB were treated with adefovir disoproxil
(GSK Pharma UK) 10mg once daily. All of the patients
met the most recent European guideline criteria for treat-
ment of CHB [34] and were followed up for 24 weeks.
Peripheral EDTA anticoagulant blood samples were obtained
from individual participants before and after the treatment
longitudinally.
2.3. Viral Genotyping, Viral Load and Other Biochemi-
cal Measurements. HBVserology (HbsAg/Anti-HBs,HbeAg/
Anti-Hbe,quantitative HbsAg, quantitative HbeAg) were
determined by microparticle enzyme immunoassay (MEIA).
The virus loads in individual plasma samples were measured
by quantitative PCR using Roche COBAS Taqman HBV
test (Roche, UK), and the limitation of detecting HBV
was 20 IU/mL.The levels of serum aspartate aminotrans-
ferase (AST) and alanine transaminase (ALT) were detected
by Biochemistry Automatic Analyzer (Roche Diagnostics,
Branchburg, USA).
2.4. Flow Cytometry Analysis. To determine the percentages
of diﬀerent subsets of NK cells, anticoagulated blood was
incubated for 30min with a cocktail of allophycocyanin
(APC)-conjugated CD56 (clone B159), fluorescence isoth-
iocyanate (FITC)-conjugated CD3 (clone UCHT1), and
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Table 1: Characteristics of study population.
Healthy controls (n = 12) ADV-group (baseline, n = 12) TDF-group (baseline, n = 12)
Age, years (mean ± SEM) 35.9 ± 10.1 33.5 ± 5.9 35.2 ± 6.44
Sex
Female/male (%) 2/10 (17/83) 2/10 (17/83) 5/7 (42/58)
ALT, IU/mL (median (IQ range)) n.a 125.5 (65–383) 123.5 (95–358)
HBV-DNA mean log 10 IU/mL ± SEM n.a 7.7 ± 0.9 7.5 ± 1.0
HBeAg
Positive/negative n.a 8/4 7/5
HBV genotype
Genotype B/C 2/10 0/12
Abbreviations: SEM: standard error of mean, IQ: interquartile, n.a.: not applicable.
PerCP-Cy 5.5-conjugated CD16 (clone 3G8), and stained
with PE-conjugated antibodies against CD158a (clone HP-
3E4), CD158b (clone CH-L), NKp30 (clone P30-15), NKp44
(clone p44-8.1), NKp46 (clone 9E2/Nkp46, BD PharMinge,
San Diego, USA), NKB1 (clone DX9, BD Biosciences,
Belgium), KIR2DL3 (clone 180701), NKG2D-PE (clone
149810), NKG2A (clone 131411), NKG2C (clone 134591,
R&D Systems, USA), or isotope controls, respectively. The
frequency of diﬀerent subsets of NK cells was characterized
by flow cytometry analysis.
2.5. Statistical Analysis. Data are expressed as mean values
of individual patients or median and range. The diﬀerence
between two independent groups was analyzed by the
Mann-Whitney U test, and the diﬀerence between paired
variables by theWilcoxon matched-pairs test using the Prism
5.0 (GraphPad software, USA). The potential correlation
between two variables was analyzed by the Spearman’s rank
correlation coeﬃcient test. A two-tailed P value of less than
0.05 was considered statistically significant.
3. Result
3.1. Alteration in the Frequency of NK Cells Is Associated with
Liver Damage in CHB Patients. To determine the frequency
of NK cells, 24 CHB patients and 12 healthy age and
gender matched subjects were recruited into this study. CHB
patients displayed high concentrations of ALT and HBV
loads (Table 1).
Characterization of peripheral blood NK cells by
flow cytometry analysis indicated that the frequency of
CD3−CD56+ NK cells in CHB patients was lower than that
in healthy controls (Figures 1 and 2). Furthermore, analysis
of diﬀerent subsets of NK cells revealed that the frequency
of activating receptor NKp30+ NK cells in CHB patients was
significantly higher than that in healthy controls while the
frequency of inhibitory receptor CD158b+ NK cells in CHB
patients was found to be significantly lower than that in
healthy controls(Figures 1 and 3).We observed no significant
diﬀerence in the expression of NKp44, NKp46, NKG2A,
NKG2C, NKG2D, NKB1, and CD158a between the health
controls and CHB patients. Interestingly, the concentrations
of plasma ALT in CHB patients were negatively associated
Table 2: Virological outcomes to tenofovir or adefovir.
Time point TDF ADV
Baseline 8.01 (6.22–9.22) 7.81 (5.89–8.86)
4 weeks 5.16 (2.91–6.77)∗ 4.58 (2.79–6.33)∗
8 weeks 2.95 (2.34–5.98)∗ 3.58 (1.89–5.96)∗#
12 weeks 2.42 (1.62–5.47)∗ 2.83 (1.88–5.63)∗
24 weeks 1.85 (1.3–4.8)∗ 2.21 (1.3–5.57)∗
Compare with the initial of the treatment, ∗P < 0.05; compare with two
drugs, #P < 0.05.
with the frequency of CD158b+ NK cells in CHB patients
(Figure 4). These data indicated that alteration in the
frequency of NK cells was associated with liver damage in
CHB patients.
3.2. Patients Have Diﬀerent Therapeutic Response to TDF and
ADV Treatment. These patients were treated with tenofovir
or adefovir. In patients treated with tenofovir or adefovir,
ALT, AST, and HBV DNA were markedly reduced after
initiation of therapy. There were 7 patients (rate = 58%)
whose HBV DNA reaches <3log10 IU/mL in the TDF treated
group while only one patient’s HBV DNA reaches this level
in ADV treated group (rate = 8.3%) (Table 2). The viral
response rate of TDF-group (HBV DNA< 3log10 IU/mL)
was significantly higher than ADV-group at 8 weeks (P =
0.028, Fisher test). In seven HBeAg-positive patients at
24 weeks after treatment of Tenofovir disoproxil, three
cases achieved HBeAg seroconversion. However, no HBeAg
seroconversion occurred in 8 patients with adefovir dipivoxil
treatment. Therefore, diﬀerent treatments may yield diﬀer-
ent responses, TDF at a daily dose of 300mg had superior
antiviral eﬃcacy compared with ADV at a daily dose of 10mg
through week 24.
3.3. Treatment with Tenofovir or Adefovir Alters the Frequency
of Diﬀerent Subsets of NK Cells in CHB Patients. We next
examined the impact of diﬀerent treatments on the changes
of NK cells. We found that the frequency of NK cells
transiently increased in tenofovir treated group at 8, 12,
and 24 weeks after initial treatment (Figure 5). These data
clearly indicated that treatment with tenofovir modulated
the frequency of NK cells.
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Figure 1: Characterization of diﬀerent subsets of NK cells. The frequency of diﬀerent subsets of NK cells was determined by flow cytometry
analysis using specific antibodies. Briefly, peripheral blood mononuclear cells were prepared from individual subjects and stained with a
cocktail of APC-anti-CD56 and FITC-anti-CD3 and the cells were gated on CD3−CD56+ as NK cells. Furthermore, the cells were stained with
APC-anti-CD56 and PE-conjugated antibodies against CD158a, or CD158b, NKp30, NKp44, NKp46, NKB1, KIR2DL3, NKG2D, NKG2A,
NKG2C, or isotope controls, respectively, for characterizing the frequency of diﬀerent subsets of NK cells. Data shown are representative
charts of flow cytometry analysis of some subsets of NK cells.
Given that diﬀerent subsets of NK cells have diﬀerent
functions, we characterized the frequency of diﬀerent subsets
of NK cells longitudinally after treatment. Treatment with
tenofovir or adefovir decreased the frequency of NKG2A+
and KIR2DL3+ NK cells at 12 and 24 or 24 weeks after
initial treatment in both groups of CHB patients (Figure 6),
respectively. In contrast, treatment with adefovir significantly
increased the frequency of CD158b+ NK cells at 24 weeks
after initial treatment in CHB patients (Figure 7).
Therefore, treatment with diﬀerent kinds of nu-
cleos(t)ide analogues (NUCs) had diﬀerential eﬀects on
modulating activating and inhibitory receptor+ NK cells in
CHB patients.
4. Discussion
In this study, we examined the frequency of diﬀerent subsets
of NK cells in patients with CHB following nucleos(t)ide
analogues (NUCs) antiviral therapy. We found that, there
was significant diﬀerence in the frequency of NK cells
between CHB patients and healthy controls, the frequency of
NKp30+ NK cells in CHB patients was significantly higher
than those in healthy controls. In contrast, the frequency
of CD158b+ NK cells in CHB patients was significantly
lower than that in healthy controls. More interestingly, the
concentrations of serum ALT were negatively correlated with
the percentages of CD158b+ NK cells in CHB patients. These
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Figure 2: Characterization of NK cells at baseline. The percentages
of NK cells in lymphocytes. Data are expressed as mean ± SEM.
∗∗∗P < 0.001.
data indicated that a lower frequency of inhibitory receptor+
NK cells contributed to liver damages. Apparently, a lower
frequency of CD158b+ NK cells may be valuable for the
evaluation of liver damage in CHB patients.
Previous studies have shown controversial results on the
frequency of NK cells in CHB patients following standard
therapies [33, 35]. We treated CHB patients with tenofovir
or adefovir and characterized the frequency of diﬀerent
subsets of NK cells by flow cytometry analysis. We found that
treatment with tenofovir transiently increased the frequency
of NK cells in CHB patients at 4, 12, and 24 weeks
after initiation of treatment. In contract, the frequency of
NK cells does not change significantly over the course of
treatment with adefovir. These data suggest that treatment
with tenofovir may promote NK cell proliferation during the
early periods after treatment. Maybe because of TDF had
superior antiviral eﬃcacy compared with ADV.
Characterization of diﬀerent subsets of NK cells indi-
cated that treatment with the antiviral therapy transiently
decreased the frequency of NKG2A+ and KIR2DL3+ NK cells
after treatment. More importantly, the decreased percentages
of NKG2A+ NK cells were negatively correlated with the
reduced levels of HBV loads in CHB patients early after
treatment. These data were similar to that of previous reports
in chronic hepatitis B virus infected and chronic hepatitis
C virus infected patients [32, 36]. Although we could not
establish significant correlations between the expression of
NK cell receptors, such as NKG2A, KIR2DL3, and activation
status of function, it does not exclude a role for these
receptors in the regulation of NK cell activation and/or
function. Since NKG2A triggering have been shown to
regulate IFN-γ production [37, 38], it is tempting to spec-
ulate that in chronic HBV infection, increased expression
of NKG2A prohibits NK cells from being activated and
from functioning. In that respect, the downregulation of
NKG2A upon viral load reduction as demonstrated herein
may be in part responsible for the improvedNK cell function.
These data suggest that NKG2A+ NK cells are crucial for the
clearance of HBV in CHB patients and that the frequency
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Figure 3: Expression of activating and inhibitory receptors on NK
cells in patients with chronic HBV infection. The frequency of
activating receptors NKp30 and inhibitory receptors CD158b on
NK cells in peripheral blood of 12 healthy controls (HC) and 21
sex and age-matched chronic HBV patients (HBV) (mean ± SEM
HBV-DNA 10log 7.5±0.9 IU/mL, ALT 167±96 IU/mL, 9 e-negative
Ag) was determined by FACS analysis. Data show the individual
and the mean percentage of expressing cells within the total NK cell
population. ∗P < 0.05.
of peripheral blood NKG2A+ NK cells may be a valuable
biomarker for the evaluation of HBV clearance in CHB
patients.
The balance of activating signals via NCR and inhibitory
signals via KIR is crucial for systemic NK cell responses,
and HBV infection can modulate the interplay between
inhibitory and activation signals [39, 40]. To further under-
stand the mechanisms of therapy-induced antiviral immune
responses, we characterized the frequency of diﬀerent subsets
of NK cells in CHB patients with diﬀerent NUCs treatments.
We found that treatment with either protocol decreased
the frequency of NKG2A+, KIR2DL3+NK cells later after
treatment. Apparently, treatment with NUCs down-regulates
inhibitory receptor expression in NK cells in CHB patients.
These data further indicate that downregulates inhibitory
receptor expression in NK cells which can increase NK
activity is associated with the clearance of HBV in CHB
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Figure 4: Liver injury was negatively correlated with inhibitory
receptor CD158b expression on NK cells. The potential correlation
of the percentages of NK cells with the levels of serum ALT in CHB
patients was analyzed.
patients. Therefore, given that treatment with antiviral
therapy significantly reduced the levels of plasma HBV loads
and serum ALT, the higher frequency of NK cells and
decreased inhibitory receptors suggested that activated NK
cells participated in the clearance of HBV in CHB patients.
We compared the diﬀerent subsets between tenofovir group
and adefovir group, adefovir promoted the percentage of
CD158b+ NK cells. The frequency of CD158b+ NK cells
significantly correlates with the ALT level in CHB patients
before initiation of antiviral treatment. The increased per-
centage of CD158b+ NK cells may be associated with the
decreased concentrations of plasma ALT.
Several groups have studied NK cells during the antiviral
treatment of CHB patients, but the results regarding NK
cell frequency and receptor expression are conflicting [32,
40, 41]. This probably reflects the complexity of activating
and inhibiting signals that control NK cells. One important
question is how the responses of individual patients to
the antiviral therapy are associated with the change in
the frequency of diﬀerent subsets of NK cells. We noted
a rapid decline in expression of NKG2A and KIR2DL3,
but not activating receptors, following the administration
of NUCs. This implies that these cells have this balance
altered in favour of activation. Viral load reduction may
be an indirect eﬀect on NK cells due to changes in the
cytokine milieu, or due to interactions with other cells of
the immune system that can subsequently eﬀect NK cell
receptor expression. During the treatment of CHC patients,
the frequency of NKG2A+ and KIR2DL3+ NK cells in the
EVR group was significantly higher than those in the non-
EVR group [42]. Interestingly, a recent study has shown
that KIR2DL3+ NK cells have higher degranulation activity
in patients with self-limited HCV infection [43]. Diﬀerent
from hepatitis C treatment, besides the decrease of viral load,
HbeAg seroconversion was also an important standard to
judge the antiviral eﬀect. In this study, subjects of HbeAg
seroconversion were limited to analysing the diﬀerence
frequency of NKG2A+ and KIR2DL3+ NK cells bewteen
HbeAg seroconversion and none-HbeAg seroconversion at
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Figure 5: Antiviral treatment TDF but not ADV results in increase
of NK cells. Data are presented as mean ± SEM (a). ∗∗P < 0.01,
∗∗∗P < 0.001 Data are expressed as mean ± SD of the percentages
of NK in 12 patients treated with tenofovir (a) or adefovir (b) at the
indicated time points after treatment. (a, b): the percentages of NK
cells in lymphocytes.
24 weeks after initial treatment. We will analyse it in the
followup.
Therefore, the frequency of NKG2A+ and KIR2DL3+
NK cells may be a prognostic marker for the evaluation of
individual responses to the standard therapy in the clinic.
In summary, our data indicate that the frequency of
CD3−CD56+ NK cells in CHB patients was lower than that in
healthy controls, the frequency of NKp30+NK cells in CHB
patients was significantly higher than those in healthy con-
trols. In contrast, the frequency of CD158b+ NK cells in CHB
patients was significantly lower than that in healthy controls.
The percentages of inhibitory CD158b+ NK cells were
negatively associated with liver damage in CHB patients.
Treatment with the tenofovir therapy transiently increased
the frequency of NK and decreased frequency of inhibitory
receptor+ NK cells in CHB patients. Therefore, our findings
Mediators of Inflammation 7
0
20
40
60
80
100
N
K
G
2A
 (
%
)
Time after treatment (week)
0 12 24
∗∗
∗
(a)
0
20
40
60
80
100
K
IR
2D
L3
 (
%
)
Time after treatment (week)
0 12 24
∗∗
(b)
N
K
G
2A
 (
%
)
0
20
40
60
80
Time after treatment (week)
0 12 24
∗∗
∗
(c)
K
IR
2D
L3
 (
%
)
0
20
40
60
80
Time after treatment (week)
0 12 24
∗∗
(d)
Figure 6: Antiviral treatments results in decrease of NKG2A and KIR2DL3 expression in patients with chronic HBV infection treated with
tenofovir or adefovir. The frequency of NKG2A and KIR2DL3 expressing NK cells at baseline (0w), 12w, and at 24w of therapy. Data are
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Figure 7: The eﬀect of treatment with ADV on the frequency of CD158b+ NK cells in CHB patients. Data are expressed as mean values of
individual patients at the indicated time points after treatment.
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provide a unique insight in the NK cell compartment in
CHB patients during tenofovir induced viral load reduction.
Our study demonstrates modest changes in the frequency
of inhibitory receptor+ NK cells after successful antiviral
therapy. We recognized that our study had limitations of
small sample size and the lack of analysis of NK cells function
and NK cells in the target tissue. Thus, further studies with
a large population, combined with liver tissue analysis, NK
cells function, to validate the findings are warranted.
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